ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

beruzatatug pelitecan

Also written as “YL202”, “BNT326” and “YL202 should be intravenously infused”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Melanoma, led by 2 companies.

Drug pageBeruzatatug pelitecan: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 10, 20269 company-led studies, 9 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MediLink Therapeutics (Suzhou)its history only77 open or runningphase 3since Feb 10, 2026Dec 1, 2022Nov 2026phase 2 · NCT06107686
BioNTech22 open or runningphase 2since Jul 3, 2025Jul 3, 2025Mar 2028phase 2 · NCT07070232

Also a collaborator on its studies: BioNTech (Shanghai) Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of BioNTech only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 3, 2025First study: phase 2 study in Lethal Congenital Contracture Syndrome 2First studyNCT07070232 · 1,438 planned · United States, Australia, Belgium and more
  2. Aug 1, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07111520 · 880 planned · United States, Australia, China and more
  3. Jan 29, 2026Named beruzatatug pelitecanINNProposed as its International Nonproprietary Name in WHO's List 134 · before, YL202, BNT326

Ahead

  1. Mar 2028Primary completion: phase 2 study in Lethal Congenital Contracture Syndrome 2NCT07070232
  2. Nov 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07111520

TargetBeta

ERBB3 →read by rule
“An antibody-drug conjugate (ADC) composed of beruzatatug, an immunoglobulin G1 (IgG1) monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3; ErbB3) ”NCIt, by rule

Other programs on ERBB3

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
patritumab deruxtecanMerckphase 317
ruzaltatug rezetecanJiangsu HengRui Medicinephase 38
JSKN016ruleAlphamab Oncologyphase 35
SYS6023ruleCSPC Pharmaceutical Groupphase 22
Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002rulexadcera-biopharmaceutical-suzhou-co-ltdphase 21
Anti-HER3/Exatecan Antibody-drug Conjugate ENV-501rulehummingbird-biosciencephase 21
Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418ruleavenzo-therapeutics-incphase 21
KHN922ruleChengdu Kanghong Pharmaceutical Groupphase 21
CS5007ruleCStone Pharmaceuticalsphase 11
JSKN016HCruleAlphamab Oncologyphase 11

Studies

All 2 BioNTech leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07111520Carcinoma, Non-Small-Cell Lung · United States, Australia, China and more2RecruitingNov 2028880
NCT07070232Lethal Congenital Contracture Syndrome 2 · United States, Australia, Belgium and more2RecruitingMar 20281,438

How it is read

Names in the registry

  • “YL202”, 4 entries
  • “BNT326”, 2 entries
  • “YL202 should be intravenously infused”, 2 entries
  • “YL202 for injection; Toripalimab injection”, 1 entry
  • “YL202 for injection; Furmonertinib Mesilate Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.